FOR UK HEALTHCARE PROFESSIONALS ONLY

About Sevodyne

Welcome to sevodyne.co.uk

Sevodyne (buprenorphine) transdermal patches are indicated for the treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.1

Available as:

  • Transdermal patch 5 microgram/hr

  • Transdermal patch 10 microgram/hr

  • Transdermal patch 15 microgram/hr

  • Transdermal patch 20 microgram/hr

Sevodyne transdermal patches are bioequivalent to Norspan® (buprenorphine) (Mundipharma GmbH, Germany)/BuTrans® (buprenorphine) (Napp Pharmaceuticals Ltd, UK) buprenorphine transdermal patches.2

Sevodyne could offer significant cost savings to your practice and clinical commissioning group (CCG).3*

Buprenorphine 5 microgram/hr, 10 microgram/hr, 15 microgram/hr and 20 microgram/hr transdermal patches are on the UK Drug Tariffs.3

However, the NHS could make 69% savings on the cost of buprenorphine patches by prescribing Sevodyne by brand name.3*

Quite simply a wholesale switch of buprenorphine transdermal patches 5µg/hr, 10 µg/hr, 15µg/hr and 20µg/hr prescriptions to Sevodyne could still save an average CCG £150,300 per year.4**

In addition with Sevodyne you can get:

  • Pricing not dependent on competitor activity***

  • Price guaranteed***

*Based on 69% saving on the cost of buprenorphine transdermal patches in the UK Drug Tariffs. ** Savings based on market data in reference 4. Savings calculated from 2021 spend of 132 Healthboards/CCGs switching their generic and originator brand 5, 10, 15 and 20mcg buprenorphine transdermal patch prescriptions to Sevodyne. ***No change in price subject to no material change to the products or of the UK Drug Tariffs until the 2024 PPRS review.
References: 1) Sevodyne SmPCs. 2) Data on file, 1010067149 v5.0 September 2021. 3) November 2021 UK Drug Tariffs. 4) Insypher Data July 2021 Based on Annual Moving Total (UK)

TRUSTED BRANDS.
DEPENDABLE SUPPLY CHAIN.

For further information please call: 01730 231148,
email: customerservices@aspirepharma.co.uk or visit www.aspirepharma.co.uk
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Sevodyne, please see the abbreviated prescribing information.

Revision reference – Sevodyne_11_29.11.2021

More products available
in this range:
Click to view their
individual websites